dgx-20260618

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 11-K

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2025

o TRANSITION REPORT PURSUANT TO SECTION 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______to _______

Commission file number: 001-12215

A. Full title of the plan and the address of the plan, if different from that of the issuer named below:

THE QUEST DIAGNOSTICS PROFIT SHARING PLAN

B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

QUEST DIAGNOSTICS INCORPORATED

500 PLAZA DRIVE

SECAUCUS, NJ 07094

The Quest Diagnostics Profit Sharing Plan

Index to Financial Statements and Supplemental Schedule


			Page
Financial Statements

Report of Independent Registered Public Accounting Firm			1

Statements of Net Assets Available for Benefits as of December 31, 2025 and 2024			2

Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2025			3

Notes to Financial Statements			4

Supplemental Schedule*

Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year) as of December 31, 2025			9

Signature			14

* Other schedules required by Section 2520.103-10 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA have been omitted because they are not applicable.

Exhibit
Exhibit 23 - Consent of Independent Registered Public Accounting Firm

Report of Independent Registered Public Accounting Firm

Plan Administrator and Plan Participants

The Quest Diagnostics Profit Sharing Plan

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of The Quest Diagnostics Profit Sharing Plan (the “Plan”) as of December 31, 2025 and 2024, the related statement of changes in net assets available for benefits for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2025 and 2024, and the changes in net assets available for benefits for the year ended December 31, 2025 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2025 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan's auditor since 2008.

Melville, New York

June 18, 2026

The Quest Diagnostics Profit Sharing Plan

Statements of Net Assets Available for Benefits

December 31, 2025 and 2024

(in thousands)


	2025		2024
Assets
Cash	$	4	$	—
Investments, at fair value	6,158,117		5,483,306
Receivables

Notes receivable from participants	70,137		70,809
Investment related receivables	735		1,031
Total receivables	70,872		71,840
Total assets	6,228,993		5,555,146

Liabilities
Investment related payables	405		1,376



Net assets available for benefits	$	6,228,588	$	5,553,770

The accompanying notes are an integral part of these financial statements.

The Quest Diagnostics Profit Sharing Plan

Statement of Changes in Net Assets Available for Benefits

For the Year Ended December 31, 2025

(in thousands)


Additions:
Investment income
Net appreciation in fair value of investments	$	918,980
Dividends and interest	18,693
Total investment income	937,673

Interest income on notes receivable from participants	5,657

Contributions
Employer	106,159
Participants	204,797
Rollovers	31,009
Total contributions	341,965

Total additions	1,285,295


Deductions:
Benefits paid to participants	608,446
Administrative expenses	2,031
Total deductions	610,477

Net increase	674,818



Net assets available for benefits:
Beginning of year	5,553,770

End of year	$	6,228,588

The accompanying notes are an integral part of these financial statements.

The Quest Diagnostics Profit Sharing Plan

December 31, 2025 and 2024

Notes to Financial Statements (dollars in thousands)

1. Description of the Plan

Background - The Quest Diagnostics Profit Sharing Plan (the “Plan”) is a defined contribution plan. The Plan was established by Quest Diagnostics Incorporated ("Quest Diagnostics" or the "Company"), which is the parent entity of a controlled group of corporations and other entities (the "Quest Control Group"). Effective August 15, 2021, sponsorship of the Plan was transferred from the Company to Quest Diagnostics Clinical Laboratories, Inc. (the "Plan Sponsor"), a wholly owned subsidiary of the Company. The Plan provides retirement benefits to eligible employees of the Quest Control Group. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The following description of the Plan provides only general information. Participants should refer to the plan document for a more complete description of the Plan's provisions.

Eligibility and Participant Contributions - The Plan provides for participant-directed investment of their voluntary contributions and employer matching contributions in a number of investment funds. Eligible employees can participate in the Plan as soon as administratively feasible upon becoming an employee of a member of the Quest Control Group. Participants may contribute an amount between 1% and 35% of their eligible compensation, as defined, for the contribution period. Catch-up contributions, as defined in the Internal Revenue Code (the "Code"), are permissible for eligible participants. Participants may modify their contribution percentage at any time. Participants may also choose to make rollover contributions to the Plan of amounts received from an eligible defined benefit or defined contribution plan maintained by another company. Contributions are subject to Code limitations.

Employer Matching Contributions - Members of the Quest Control Group match 100% of a participant's contribution, up to 5% of eligible compensation, in cash after the participant completes 12 months of service, as defined, with the Quest Control Group. Employer matching contributions are remitted to the Plan at the same time that the corresponding participants' contributions are remitted.

Participant Accounts - A separate individual account is established for each Plan participant. Each participant's account is credited with the participant's contributions and the employer matching contributions, plus the allocation of investment earnings, gains and losses and expenses, based on participant earnings or account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant’s vested account.

Vesting - Participants immediately vest in their voluntary contributions and employer matching contributions plus actual earnings thereon. Certain participants who were active in plans sponsored by previous employers have vesting requirements applied to their previous employer contribution accounts consistent with the vesting requirements in effect before the assets were merged into the Plan.

Investment Options - Participants may elect to have their voluntary contributions and employer matching contributions invested in any or all of the available investment options, most of which are managed by Fidelity Management & Research Company (“FMRC”) and its affiliates. Participants may also elect to have their voluntary contributions and employer matching contributions invested in shares of the Company's common stock through the Quest Diagnostics stock fund. Participants have the ability to modify their investment elections daily, subject to certain short-term trading restrictions imposed by FMRC and its affiliates and the Company's securities trading policy, which prohibits trading in the Company's common stock on a short-term basis and while in possession of material non-public information about the Company.

Participants cannot contribute greater than 25% per pay period of pre-tax contributions into the Quest Diagnostics stock fund. In addition, participants can transfer monies into the Quest Diagnostics stock fund only to the extent the percentage of holdings in the Quest Diagnostics stock fund after the transfer remains below 25% of the participant's entire account balance.

Participants may elect to receive their dividends on investments in the Quest Diagnostics stock fund as a taxable cash payment or to have those dividends automatically reinvested.

Distribution Options - Participants can elect to have their benefit distributions, equal to the value of the vested portion of their account balance, paid in the form of a partial or lump sum distribution, a direct rollover into another eligible retirement plan or traditional individual retirement account, installment payments, or for certain assets, an annuity.

The Quest Diagnostics Profit Sharing Plan

December 31, 2025 and 2024

Notes to Financial Statements (dollars in thousands) - continued

Withdrawals - Withdrawals may be made for qualified emergencies, as defined in the Code. Depending upon the type of withdrawal and the status of the contribution, penalties upon withdrawal may apply. Participants may also begin to make withdrawals without penalty at age 59 ½, subject to certain limitations as defined by the Plan.

Forfeitures - Employer contributions in forfeited nonvested accounts may be used to reduce future employer contributions or pay the Plan's expenses. The forfeiture activity and account balance was not material as of and for the years ended December 31, 2025 and 2024.

Parties-in-Interest - Certain investments of the Plan, as of December 31, 2025 and 2024, are shares of mutual funds and collective funds managed by FMRC and its affiliates. These transactions qualify as party-in-interest transactions.

The Company also is a party-in-interest to the Plan under the definition provided in Section 3(14) of ERISA. Therefore, Quest Diagnostics stock transactions qualify as party-in-interest transactions. As of December 31, 2025 and 2024, the total fair value of the Plan's investment in Quest Diagnostics stock was $310,165 and $295,103, respectively. During 2025, there were no purchases of Quest Diagnostics stock by the Plan and sales of Quest Diagnostics stock by the Plan were $29,226.

Notes Receivable from Participants - Participants are permitted to obtain loans in amounts not less than one thousand dollars and up to the lesser of (1) fifty thousand dollars, subject to certain limitations as defined by the Plan, or (2) 50% of the participant's vested portion of their account value. Except with respect to pre-existing loans transferred or merged into the Plan and as set forth below, a participant may have only one outstanding loan at a time and loans are repayable over a period of up to five years, unless the proceeds are used to purchase a primary residence, in which case a period of up to thirty years (effective January 2025) is permitted. Loans are secured by one-half of a participant's vested account balance and bear interest at prime plus 1%. Rates range from 3.25% to 10.50%; maturities vary by participant. Principal and interest are repaid to the Plan through payroll deductions for active employees. Participants can elect to pay the entire outstanding balance of a loan directly to Fidelity Management Trust Company ("FMTC"). Actively employed participants can also submit a partial loan repayment directly to FMTC outside the normal payroll deductions, accelerating the payoff date. Participants who are no longer active employees may continue to repay outstanding loan balances directly to FMTC.

In addition, notes receivable from participants qualify as party-in-interest transactions. As of December 31, 2025 and 2024, the carrying value of the Plan's notes receivable from participants was $70,137 and $70,809, respectively.

Plan Administration - The plan administrator is the Benefits Administration Committee (the "Plan Administrator"), which is appointed by the Plan Sponsor's Board of Directors. The Plan's trustee and recordkeeper for the Plan investments are FMTC and Fidelity Investments Institutional Operations Company LLC, respectively.

Tax Status - The Internal Revenue Service (“IRS”) has determined and informed the Company by letter dated September 22, 2014, that the Plan and related trust are designed in accordance with applicable sections of the Code. The Plan Sponsor believes that the Plan, which has been amended since the IRS determination, continues to be designed and operated in compliance with the applicable requirements of the Code and, therefore, believes that the Plan is qualified and related trust is tax-exempt.

Accounting principles generally accepted in the United States (“US GAAP”) requires the Plan Administrator to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2025 and 2024 there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing authorities; however, there are currently no audits for any tax periods in progress.

Administrative Expenses - Plan administrative expenses are paid by the Company to the extent not paid or offset by the Plan or the Quest Control Group. Fees associated with the administration of notes receivable from participants are charged directly against participant accounts. These fees are included in administrative expenses and are expensed when incurred. Investment related expenses are included in net appreciation of fair value of investments.

The Quest Diagnostics Profit Sharing Plan

December 31, 2025 and 2024

Notes to Financial Statements (dollars in thousands) - continued

Investment Management Fees - Investment management fees and operating expenses charged to the Plan for investments in the Plan are deducted from income earned on a daily basis and are not separately reflected. Consequently, investment management fees and operating expenses are reflected as a reduction of investment return for such investments.

Plan Termination - The Plan Sponsor intends to continue the Plan indefinitely, but reserves the right to change or discontinue the Plan at its discretion. Participants will become fully vested in their rights under the Plan if it is terminated or if employer matching contributions are completely discontinued.

2. Summary of Significant Accounting Policies

Basis of Presentation - The Plan maintains its financial records on the accrual basis of accounting.

Use of Estimates - The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, if any, at the date of the financial statements and the reported amounts of additions to and deductions from net assets during the reporting period. Actual results could differ from those estimates.

Risks and Uncertainties - Certain underlying investment securities are exposed to various risks, such as interest rate, market and credit risk. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, changes in these risks could materially affect participants' account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statement of Changes in Net Assets Available for Benefits.

Benefits paid to participants - Benefits payments to participants are recorded when paid.

Valuation of Investments - Investments are stated at fair value at year end. Refer to Note 3 for additional information related to the valuation of Plan investments.

Security Transactions and Income - Purchases and sales of securities are recorded on a trade-date basis. Dividend income is recorded on the ex-dividend date. Interest income from investments is recorded as earned on an accrual basis.

Net appreciation in fair value of investments represents the Plan's net realized and unrealized gains (losses) on investments held by the Plan.

Notes Receivable from Participants - Notes receivable from participants are valued at their unpaid principal balance, plus any accrued but unpaid interest. Interest income from notes receivable from participants is recorded on an accrual basis.

3. Fair Value Measurements

Fair value measurements are based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, and are determined by either the principal market or the most advantageous market.

Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest.

The Quest Diagnostics Profit Sharing Plan

December 31, 2025 and 2024

Notes to Financial Statements (dollars in thousands) - continued


Level 1:			Quoted prices in active markets for identical assets or liabilities.

Level 2:			Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3:			Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

During the year ended December 31, 2025, there were no transfers between levels.

The following table provides a summary of the assets in the Plan that are measured at fair value on a recurring basis:


			Basis of Fair Value Measurements

December 31, 2025	Total		Level 1		Level 2		Level 3
Mutual funds	$	212,232	$	212,232	$	—	$	—
Quest Diagnostics common stock	310,165		310,165		—		—
Other common stock	287,320		287,320		—		—


Subtotal	$	809,717	$	809,717	$	—	$	—

Investments measured at NAV as a practical expedient: (A)	5,348,400

Total investments, at fair value	$	6,158,117


			Basis of Fair Value Measurements
December 31, 2024	Total		Level 1		Level 2		Level 3
Mutual funds	$	204,410	$	204,410	$	—	$	—
Quest Diagnostics common stock	295,103		295,103		—		—
Other common stock	282,820		282,743		—		77


Subtotal	$	782,333	$	782,256	$	—	$	77

Investments measured at NAV as a practical expedient: (A)	4,700,973

Total investments, at fair value	$	5,483,306

(A) Certain investments, including the Collective Funds, that were measured at fair value using the net asset value ("NAV") per share (or its equivalent) practical expedient were not classified in the fair value hierarchy. There are no unfunded commitments or redemption restrictions related to these investments.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used as of December 31, 2025 and 2024.

Mutual Funds: Valued at the daily closing price reported by the fund. Mutual funds held by the Plan are open-ended mutual funds that are registered with the Security and Exchange Commission ("SEC") and are required to publish their NAV on a daily basis and to transact at that price. The mutual funds held by the Plan are classified as level 1.

The Quest Diagnostics Profit Sharing Plan

December 31, 2025 and 2024

Notes to Financial Statements (dollars in thousands) - continued

Quest Diagnostics Common Stock and Other Common Stock classified as level 1: Valued at the closing price reported on the active market on which the individual securities are traded.

Other Common Stock classified as level 3: Valued using a valuation technique based on available information, which may consider market-based valuation multiples; a discount or premium from market value of a similar, freely traded equity security of the same issuer; or some combination. These fair value measurements are classified within Level 3 of the fair value hierarchy as the fair value is based on significant inputs that are not observable.

Collective Funds: Valued at NAV per unit as determined by the trustee at year end. The NAV is used as a practical expedient to estimate fair value.

The preceding methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

4. Commitments and Contingencies

In 2020, two putative class action lawsuits were filed in the U.S. District Court for New Jersey against the Company and other defendants with respect to the Plan. The complaint alleges, among other things, that the fiduciaries of the Plan breached their duties by failing to disclose the expenses and risks of plan investment options, allowing unreasonable administration expenses to be charged to plan participants, and selecting and retaining high cost and poor performing investments. The Plan itself is not named as a defendant. In October 2020, the court consolidated the two lawsuits under the caption In re: Quest Diagnostics ERISA Litigation and plaintiffs filed a consolidated amended complaint. In May 2021, the court denied the Company's motion to dismiss the complaint. After discovery was completed, the Company filed a motion for summary judgment, which was granted. The matter is on appeal.

The Quest Diagnostics Profit Sharing Plan

EIN: #38-2084239 Plan: #333

Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)

December 31, 2025 (dollars in thousands)

(a)

(b)
Identity of Issue, Borrower, Lessor, or Similar Party

(d)
Cost

(e)
Current
Value

Fidelity Freedom Blend 2010 T

Collective Fund

***

19,293

Fidelity Freedom Blend 2015 T

Collective Fund

***

51,191

Fidelity Freedom Blend 2020 T

Collective Fund

***

161,359

Fidelity Freedom Blend 2025 T

Collective Fund

***

408,245

Fidelity Freedom Blend 2030 T

Collective Fund

***

656,013

Fidelity Freedom Blend 2035 T

Collective Fund

***

593,796

Fidelity Freedom Blend 2040 T

Collective Fund

***

474,987

Fidelity Freedom Blend 2045 T

Collective Fund

***

358,119

Fidelity Freedom Blend 2050 T

Collective Fund

***

241,734

Fidelity Freedom Blend 2055 T

Collective Fund

***

154,613

Fidelity Freedom Blend 2060 T

Collective Fund

***

86,956

Fidelity Freedom Blend 2065 T

Collective Fund

***

35,726

Fidelity Freedom Blend Income T

Collective Fund

***

19,341

Fidelity Managed Income Portfolio II - Class 3

Collective Fund

***

153,848

Fidelity Contrafund Comingled Pool

Collective Fund

***

487,077

Fidelity OTC Comingled Pool

Collective Fund

***

362,812

Spartan 500 Index Pool Class F

Collective Fund

***

737,911

Spartan Extended Market Index Pool Class F

Collective Fund

***

50,200

Spartan Total International Index Pool Class F

Collective Fund

***

56,836

GW&K Small/Mid Cap Fund

Collective Fund

***

120,332

Prudential Core Plus Bond Fund Class 15

Collective Fund

***

25,256

GQG Partners International Equity CIT Class D

Collective Fund

***

90,855

State Street Short Term Investment Fund

Collective Fund

***

1,900

Total Interest in Collective Funds

5,348,400

T Rowe Price Government Reserve Investment Fund

Mutual Fund

***

2,000

Vanguard Total Bond Market Index Fund - Institutional Plus Share Class

Mutual Fund

***

90,881

Fidelity Investments Money Market Government Portfolio - Institutional Class

Mutual Fund

***

119,351

Total Interest in Mutual Funds

212,232

Quest Diagnostics Incorporated

Common Stock

***

310,165

The Quest Diagnostics Profit Sharing Plan

EIN: #38-2084239 Plan: #333

Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)

December 31, 2025 (dollars in thousands)

(a)

(b)
Identity of Issue, Borrower, Lessor, or Similar Party

(d)
Cost

(e)
Current
Value

Accenture Plc CL A

Other Common Stock

***

534

Advanced Micro Devices Inc

Other Common Stock

***

1,678

Adyen Bv ADR

Other Common Stock

***

1,210

Agco Corp

Other Common Stock

***

824

Alliant Energy Corporation

Other Common Stock

***

267

Allstate Corporation

Other Common Stock

***

1,639

Alphabet Inc CL A

Other Common Stock

***

13,928

Alphabet Inc CL C

Other Common Stock

***

4,670

Amazon.Com Inc

Other Common Stock

***

10,240

Ameren Corp

Other Common Stock

***

1,639

American International Group

Other Common Stock

***

1,188

Amphenol Corporation CL A

Other Common Stock

***

4,715

Apple Inc

Other Common Stock

***

17,323

Applied Materials Inc

Other Common Stock

***

1,128

Applovin Corp

Other Common Stock

***

1,880

Ares Management Corp CL A

Other Common Stock

***

408

Argenx Se Sponsored ADR

Other Common Stock

***

1,534

Arista Networks Inc

Other Common Stock

***

3,005

Astrazeneca Plc Spons ADR

Other Common Stock

***

949

Avalonbay Communities Inc Reit

Other Common Stock

***

1,582

Bank Of America Corporation

Other Common Stock

***

3,068

Becton Dickinson & Co

Other Common Stock

***

896

Block Inc CL A

Other Common Stock

***

4,606

Boeing Co

Other Common Stock

***

3,023

Broadcom Inc

Other Common Stock

***

9,779

Cf Industries Holdings Inc

Other Common Stock

***

803

Chipotle Mexican Grill Inc

Other Common Stock

***

1,181

Chubb Ltd

Other Common Stock

***

2,565

Ciena Corp

Other Common Stock

***

1,029

Cigna Group (The)

Other Common Stock

***

1,849

Cisco Systems Inc

Other Common Stock

***

262

Citigroup Inc

Other Common Stock

***

2,007

Coca Cola Co

Other Common Stock

***

767

Colgate-Palmolive Co

Other Common Stock

***

1,953

Conocophillips

Other Common Stock

***

2,602

Coupang Inc A

Other Common Stock

***

1,032

Csx Corp

Other Common Stock

***

2,451

The Quest Diagnostics Profit Sharing Plan

EIN: #38-2084239 Plan: #333

Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)

December 31, 2025 (dollars in thousands)

(a)

(b)
Identity of Issue, Borrower, Lessor, or Similar Party

(d)
Cost

(e)
Current
Value

Cummins Inc

Other Common Stock

***

861

CVS Health Corp

Other Common Stock

***

1,784

Danaher Corp

Other Common Stock

***

1,116

Datadog Inc CL A

Other Common Stock

***

1,391

Disney (Walt) Co

Other Common Stock

***

950

Doordash Inc

Other Common Stock

***

1,438

Elevance Health Inc

Other Common Stock

***

2,522

Eli Lilly & Co

Other Common Stock

***

4,243

Entegris Inc

Other Common Stock

***

1,765

Eog Resources Inc

Other Common Stock

***

631

Equifax Inc

Other Common Stock

***

505

Equitable Holdings Inc

Other Common Stock

***

991

Expand Energy Corp

Other Common Stock

***

706

Exxon Mobil Corp

Other Common Stock

***

1,604

Fabrinet

Other Common Stock

***

1,161

Fifth Third Bancorp

Other Common Stock

***

271

Fortive Corp

Other Common Stock

***

1,470

GE Aerospace

Other Common Stock

***

1,255

Hartford Insurance Group Inc/The

Other Common Stock

***

1,254

Home Depot Inc

Other Common Stock

***

1,833

Howmet Aerospace Inc

Other Common Stock

***

2,717

Hubspot Inc

Other Common Stock

***

2,620

Huntington Bancshares Inc

Other Common Stock

***

1,061

Ingersoll Rand Inc

Other Common Stock

***

953

Intel Corp

Other Common Stock

***

614

International Paper Co

Other Common Stock

***

1,400

Intuit Inc

Other Common Stock

***

4,706

Intuitive Surgical Inc

Other Common Stock

***

4,072

Johnson & Johnson

Other Common Stock

***

813

Keysight Technologies Inc

Other Common Stock

***

1,228

L3Harris Technologies Inc

Other Common Stock

***

1,889

Las Vegas Sands Corp

Other Common Stock

***

730

Lattice Semiconductor Corp

Other Common Stock

***

1,447

Linde PLC

Other Common Stock

***

836

Mastercard Inc CL A

Other Common Stock

***

5,885

Mercadolibre Inc

Other Common Stock

***

1,960

Merck & Co Inc New

Other Common Stock

***

1,598

Meta Platforms Inc CL A

Other Common Stock

***

7,622

The Quest Diagnostics Profit Sharing Plan

EIN: #38-2084239 Plan: #333

Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)

December 31, 2025 (dollars in thousands)

(a)

(b)
Identity of Issue, Borrower, Lessor, or Similar Party

(d)
Cost

(e)
Current
Value

Metlife Inc

Other Common Stock

***

2,144

Microsoft Corp

Other Common Stock

***

22,859

Middleby Corp

Other Common Stock

***

748

Mongodb Inc CL A

Other Common Stock

***

1,503

Natera Inc

Other Common Stock

***

1,852

Netflix Inc

Other Common Stock

***

2,070

News Corp New CL A

Other Common Stock

***

668

Nvidia Corp

Other Common Stock

***

21,467

Philip Morris Intl Inc

Other Common Stock

***

1,514

Procter & Gamble Co

Other Common Stock

***

2,332

Qualcomm Inc

Other Common Stock

***

1,716

Rexford Industrial Realty Inc

Other Common Stock

***

1,043

Rocket Cos Inc

Other Common Stock

***

470

Rockwell Automation Inc

Other Common Stock

***

823

RPM International Inc

Other Common Stock

***

796

Salesforce Inc

Other Common Stock

***

1,512

Samsung Elec Vtg Gdr Regs

Other Common Stock

***

1,812

Sanofi Spon ADR

Other Common Stock

***

389

Schwab Charles Corp

Other Common Stock

***

3,228

Sempra

Other Common Stock

***

1,186

Servicenow Inc

Other Common Stock

***

2,408

Shopify Inc CL A

Other Common Stock

***

1,270

Siemens AG (REGD)

Other Common Stock

***

1,199

SLB Ltd

Other Common Stock

***

820

Southern Co

Other Common Stock

***

1,669

Stanley Black & Decker Inc

Other Common Stock

***

1,356

Stryker Corp

Other Common Stock

***

2,234

TE Connectivity PLC

Other Common Stock

***

310

Texas Instruments Inc

Other Common Stock

***

1,265

The Booking Holdings Inc

Other Common Stock

***

2,255

Thermo Fisher Scientific Inc

Other Common Stock

***

645

T-Mobile US Inc

Other Common Stock

***

1,118

Totalenergies SE

Other Common Stock

***

1,192

Tower Semicondctr Ltd

Other Common Stock

***

845

Tradeweb Markets Inc A

Other Common Stock

***

1,477

United Parcel Service Inc CL B

Other Common Stock

***

Unitedhealth Group Inc

Other Common Stock

***

3,061

US Bancorp Del

Other Common Stock

***

2,126

The Quest Diagnostics Profit Sharing Plan

EIN: #38-2084239 Plan: #333

Schedule H, Line 4(i) - Schedule of Assets (Held at End of Year)

December 31, 2025 (dollars in thousands)

(a)

(b)
Identity of Issue, Borrower, Lessor, or Similar Party

(d)
Cost

(e)
Current
Value

Viatris Inc

Other Common Stock

***

1,115

Visa Inc CL A

Other Common Stock

***

4,891

Walmart Inc

Other Common Stock

***

553

Wells Fargo & Co

Other Common Stock

***

1,803

Weyerhaeuser Co

Other Common Stock

***

911

Williams Companies Inc

Other Common Stock

***

523

Zimmer Biomet Hldgs Inc

Other Common Stock

***

1,930

Total Interest in Other Common Stock

287,320

Investments at Fair Value

6,158,117

Notes Receivable from Participants**

Loans

70,137

TOTAL

6,228,254

Party-in-interest to the Plan.

Rates range from 3.25% to 10.50%; maturities vary by participant.

***

The cost of participant-directed investments is not required to be disclosed.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned, hereunto duly authorized.

June 18, 2026

The Quest Diagnostics Profit Sharing Plan


By:			/s/ Cecilia K. McKenney
			Cecilia K. McKenney
			Senior Vice President, Chief Human Resources Officer and Member of the Benefits Administration Committee of Quest Diagnostics Clinical Laboratories, Inc.

SEC Form 11-K filed by Quest Diagnostics Incorporated